Climb Bio, Inc.
Climb Bio, Inc. (CLYM): 2 pipeline candidates · 1 upcoming catalyst · ~22 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
22.0 months
D/E 0.03 · 43% dilution
Lead: Phase 2
2 candidates
1 upcoming, next in ~196d
1 buy · 4 sells (180d)
A transparent, data-derived signal for Climb Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$643.6M
Cash
$8.4M
Quarterly Burn
$14.4M
Runway
22.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| budoprutug | Phase 2 |
| CLYM116 | Phase 1 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
79
Total value held
$209.6M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 11,300,939 | $77.4M |
| mpm bioimpact llc | 2,593,439 | $17.8M |
| vanguard capital management llc | 2,357,318 | $16.1M |
| braidwell lp | 1,529,675 | $10.5M |
| great point partners llc | 1,334,130 | $9.1M |
| millennium management llc | 1,276,260 | $8.7M |
| marshall wace, llp | 773,123 | $5.3M |
| affinity asset advisors, llc | 700,000 | $4.8M |
| silverarc capital management, llc | 684,908 | $4.7M |
| driehaus capital management llc | 600,946 | $4.1M |
Showing top 10 of 79 institutional holders of Climb Bio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Climb Bio, Inc.'s pipeline?
Climb Bio, Inc. (CLYM) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Climb Bio, Inc.'s lead drug candidate?
Climb Bio, Inc.'s most advanced tracked candidate is budoprutug (Phase 2) for Immune Thrombocytopenia (ITP); Healthy Volunteers; Primary Membranous Nephropathy.
What is Climb Bio, Inc.'s next catalyst?
Climb Bio, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: budoprutug" — expected December 31, 2026.
What is Climb Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Climb Bio, Inc. has approximately 22.0 months of cash runway.
What is Climb Bio, Inc.'s market capitalization?
Climb Bio, Inc.'s market capitalization is approximately $643.6M.
Get the full picture on Climb Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.